Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Morris, D."'
Autor:
Ava B. Plummer, Morris D. Groves
Publikováno v:
CONTINUUM: Lifelong Learning in Neurology. 18:421-425
Outcomes for patients with glioblastoma have improved with the addition of temozolomide (TMZ) chemotherapy to radiation therapy followed by adjuvant TMZ for up to 1 year. Patients often wish to continue chemotherapy after the standard 1-year course.
Autor:
Charles A. Conrad, Eric L. Chang, W. K. Alfred Yung, Kathy Hunter, John de Groot, Mark R. Gilbert, Morris D. Groves, Vinay K. Puduvalli, Howard Colman, S.Y. Woo, Kenneth R. Hess, Anita Mahajan, Victor A. Levin, Pierre Giglio, Javier Gonzalez
Publikováno v:
Neuro-Oncology
External beam radiation therapy (XRT) with concomitant temozolomide and 6 cycles of adjuvant temozolomide (5/28-day schedule) improves survival in patients with newly diagnosed glioblastoma compared with XRT alone. Studies suggest that dose-dense tem
Autor:
Christina A. Meyers, Victor A. Levin, W. K. Alfred Yung, Vivien Liu, Charles A. Conrad, Morris D. Groves, V. K. Puduvalli, Kathy Hunter, Kenneth R. Hess, Mark R. Gilbert
Publikováno v:
British Journal of Cancer
Background: Because of the poor outcomes for patients with recurrent glioblastoma multiforme (GBM), and some laboratory and clinical evidence of efficacy using interferon in GBM, we assessed the toxicity and efficacy of temozolomide (TMZ) combined wi
Autor:
Alfred Rademaker, Kenneth Aldape, Morris D. Groves, Charles A. Conrad, Mark R. Gilbert, Nina Paleologos, Sean Grimm, J. F. De Groot, Jeffrey Raizer, Monica Loghin, Pierre Giglio, Vinay K. Puduvalli, W. K. A. Yung, Jethro Hu, Jeremy Rudnick, Nicholas A. Vick, Brian Vaillant, Surasak Phuphanich, Diane Liu, Ryan Merrell, Marc C. Chamberlain, Ying Yuan, Ivo W. Tremont-Lukats
Publikováno v:
Journal of neuro-oncology. 126(1)
Survival for glioblastoma (GBM) patients with an unmethyated MGMT promoter in their tumor is generally worse than methylated MGMT tumors, as temozolomide (TMZ) response is limited. How to better treat patients with unmethylated MGMT is unknown. We pe
Autor:
John de Groot, Gena Volas-Redd, Shiao Y. Woo, Michael J. Fisch, Pierre Giglio, Vinay K. Puduvalli, Morris D. Groves, Michael Salacz, Mark R. Gilbert, Lore W. Lagrone, Kenneth Aldape, Howard Colman, Charles A. Conrad, Monica Loghin, Anita Mahajan, Eric L. Chang, Sigmund Hsu, W. K. Alfred Yung, Kenneth R. Hess, Victor A. Levin, Justin D. Floyd, Marta Penas-Prado, Javier Gonzalez
Despite optimal therapy with radiation and concurrent and adjuvant temozolomide (TMZ),1 survival is poor for most patients with glioblastoma (GBM), and effective second-line therapies are scarce.2,3 Even in the context of clinical trials, 3-year surv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3add5559ceb237ef1c7ea159783b291b
https://europepmc.org/articles/PMC4288521/
https://europepmc.org/articles/PMC4288521/
Autor:
Morris D, Groves, Vinay K, Puduvalli, Kenneth R, Hess, Kurt A, Jaeckle, Pamela, Peterson, W K Alfred, Yung, Victor A, Levin
Publikováno v:
Journal of Clinical Oncology. 20:1383-1388
PURPOSE: Novel therapies are needed for patients with recurrent glioblastoma multiforme (GBM). Because there is evidence that temozolomide (TMZ) has some activity in GBM and is well tolerated, and because of laboratory evidence that metalloproteinase
Autor:
W. K. Alfred Yung, Wei Qiao, Sigmund Hsu, Tobias Walbert, Vinay K. Puduvalli, Morris D. Groves, George C. Bobustuc, B. Nebiyou Bekele, Charles A. Conrad, Howard Colman, Victor A. Levin, Mark R. Gilbert
Publikováno v:
Journal of neuro-oncology. 102(2)
We evaluated the efficacy of temozolomide (TMZ) or lomustine (CCNU) in combination with 6-thioguanine, capecitabine, and celecoxib for the treatment of recurrent high-grade glioma. Forty-three patients with recurrent glioblastoma and 31 patients with
Autor:
Michelle D. Williams, Kathy Hunter, Morris D. Groves, Melesa G. Ritterhouse, Kathleen Grisdale
Publikováno v:
Journal of neuro-oncology. 100(3)
The current standard of care for patients with Glioblastoma multiforme (GBM) is surgery, followed by radiation in combination with Temozolomide (TMZ), followed by adjuvant TMZ. The most appropriate length of treatment of adjuvant TMZ after the comple
Autor:
Christina A. Meyers, Vicente Valero, Gabriel N. Hortobagyi, Thomas A. Buchholz, Kristine Broglio, Morris D. Groves, Banu Arun, Edgardo Rivera, Deborah Francis, Guosheng Yin
Publikováno v:
Cancer. 107(6)
BACKGROUND A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer. M
Autor:
Kathleen R. Lamborn, Lauren E. Abrey, Ta Jen Liu, Pamela Peterson, Susan M. Chang, Michael D. Prados, Alfred Yung, David Schiff, Kenneth R. Hess, Vinay K. Puduvalli, Ivo W. Tremont-Lukats, Patrick Y. Wen, Lisa M. DeAngelis, Timothy F. Cloughesy, Harry S. Greenberg, Mark R. Gilbert, Charles A. Conrad, Morris D. Groves
Publikováno v:
Journal of neuro-oncology. 81(3)
Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM). To determine 6-month progression-free survival (6PFS) and toxicity